The evidence here is among the oldest in the field: dronabinol (synthetic THC) carries an FDA approval for HIV-associated anorexia, and the appetite effect underlying it is well documented. Modern antiretroviral therapy has transformed the clinical picture — today's patients more often certify for neuropathic pain (a recognized HIV complication with decent cannabis evidence), nausea, sleep, and anxiety than for wasting.
Care coordination notes: documented interactions with antiretrovirals are not a major concern at patient doses, but your HIV clinician should know regardless; smoked products deserve caution at low CD4 counts (infection logic); and adherence comes first — cannabis must never compete with ART timing or consistency.
The information on this site is for educational purposes only and is not medical or legal advice. Cannabis use carries risks; consult a licensed physician about whether medical cannabis is appropriate for you. Federal status (as of June 2026): marijuana dispensed under state medical licenses and FDA-approved cannabis products are Schedule III controlled substances; all other marijuana remains Schedule I under U.S. federal law.